In response, both build-out projects and CDMOs are investigating greener methods
Last reviewed: June 11, 2026 Last updated: June 11, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Dr Bharadwaj Chada and Dr Michelle Tempest at Candesic consider the trends in the weight loss sector and why now is the time to problem solve, consolidate and invest Obesity remains one of the most pressing public health challenges of our time
In such cases, APOC3-targeted therapies may offer greater efficacy since ANGPTL3 inhibition relies on LPL-dependent pathways
Compounded Drugs and FDA-Declared Drug Shortages Due to the increased popularity of GLP-1 drugs for treatment of diabetes and for weight management, many of the FDA-approved drugs have experienced drug shortages over the past few years
This letter should explain the specific reasons for the denial, such as lack of medical necessity or failure to meet certain criteria